About This Calculator
The Tranexamic Acid Dose Calculator helps clinicians determine appropriate dosing regimens for various indications. Tranexamic acid (TXA) is an antifibrinolytic agent used to reduce bleeding by preventing the breakdown of blood clots. This tool provides weight-based and fixed-dose recommendations consistent with major clinical trials and standard medical practice.
Outputs Explained
After you input the patient's information, the calculator will provide the following outputs:
- Recommended Dosing Regimen: The specific dose, route (IV or oral), and frequency for the selected indication.
- Calculated Dose: For weight-based protocols, the exact dose in milligrams (mg) is calculated.
- Administration Notes: Important instructions, such as infusion rates (e.g., "IV over 10 minutes") and duration of therapy.
- Renal Adjustment Status: Confirms if the dose has been modified based on the calculated or provided creatinine clearance (CrCl).
How to Use the Tool
To ensure an accurate dosing calculation, please follow these steps:
- Select Patient Population: Choose between Adult and Pediatric.
- Enter Patient Weight: Input the patient's weight and select the correct unit (kg or lbs).
- Choose Clinical Indication: Select the reason for TXA administration from the dropdown menu (e.g., Trauma, Postpartum Hemorrhage).
- Specify Renal Function: Select 'Normal' if renal function is not impaired. To calculate an estimated CrCl using the Cockcroft-Gault equation, select 'Calculate' and provide the patient's age, gender, and serum creatinine. Alternatively, choose 'Direct Input' to enter a known CrCl or eGFR value.
Dosing Overview
Dosing for tranexamic acid varies significantly by indication and route of administration. The calculator incorporates the following common protocols:
- Trauma (CRASH-2): Involves a 1-gram IV loading dose followed by a 1-gram infusion over 8 hours.
- Postpartum Hemorrhage (WOMAN trial): A 1-gram IV dose, with a second dose considered if bleeding persists.
- Major Surgery (Orthopedic/Cardiac): Typically involves a weight-based IV dose (10-15 mg/kg) given pre-operatively or during the procedure.
- Menorrhagia: An oral regimen of 1300 mg taken three times daily for up to 5 days during menstruation.
- Renal Impairment: Doses, particularly for oral regimens and maintenance infusions, are reduced for patients with a CrCl below 50 mL/min to prevent drug accumulation and neurotoxicity.
Switching Between Formulations
Switching from intravenous (IV) to oral (PO) tranexamic acid is not common in acute settings. For indications requiring long-term treatment, such as Hereditary Angioedema, a transition to an oral dosing schedule is standard once the acute phase is managed. Bioavailability of oral TXA is approximately 30-50%, so doses are not directly equivalent and must be based on indication-specific oral protocols.
Missed Dose
For oral tranexamic acid regimens (e.g., for menorrhagia): If a dose is missed, the patient should take it as soon as they remember. However, if it is almost time for the next scheduled dose, they should skip the missed dose and resume their regular schedule. Patients should not take a double dose to make up for a missed one.
Safety Alerts
Thromboembolic Risk: Use with caution in patients with a history of or risk factors for thrombosis (e.g., DVT, PE).
Seizure Risk: High doses, rapid IV administration, and accumulation in renal impairment are associated with an increased risk of seizures.
Hypotension: Rapid intravenous injection may cause hypotension. IV doses should be administered as a slow infusion, typically over at least 10 minutes.
Frequently Asked Questions
- Why does the calculator need age and gender to assess renal function?
When you select "Calculate" for renal function, the tool uses the Cockcroft-Gault equation to estimate creatinine clearance. This formula requires age, weight, serum creatinine, and a correction factor for gender to provide an accurate estimate. - What is the CRASH-2 protocol?
The CRASH-2 trial was a large, randomized controlled trial that demonstrated a significant reduction in mortality when tranexamic acid was administered to trauma patients with significant bleeding. The protocol consists of a 1g IV loading dose followed by a 1g infusion over 8 hours. - How does the calculator adjust for renal impairment?
The tool reduces the dose or extends the dosing interval for patients with reduced creatinine clearance (CrCl), primarily for oral regimens. This is critical to prevent drug accumulation, which can increase the risk of side effects like seizures. - Is the use of TXA for C-section spinal hypotension standard?
The calculator includes this as an "off-label" indication. While some studies suggest a benefit in preventing hypotension after spinal anesthesia for cesarean delivery, it is not an FDA-approved use and clinical practice varies. - What happens if the IV dose is given too quickly?
Administering an IV bolus of tranexamic acid rapidly can cause a temporary drop in blood pressure (hypotension). Doses should always be infused slowly over 10-20 minutes. - Can I use this calculator for indications not listed in the dropdown?
This tool is designed only for the indications provided, as dosing is highly specific. For other uses, consult official prescribing information or institutional guidelines. - Why is there a pediatric dosing option?
Tranexamic acid is used in pediatric patients, particularly for surgery (e.g., craniofacial, cardiac, spinal) and trauma, although many uses are off-label. Doses are almost always weight-based. - Is there a maximum weight for the calculations?
The tool calculates doses based on the weight entered. For extremely obese patients, clinicians may consider using ideal or adjusted body weight for certain calculations, per institutional policy.
References
- Lysteda (tranexamic acid) Oral Tablets Prescribing Information. U.S. Food and Drug Administration.
- Cyklokapron (tranexamic acid) Injection Prescribing Information. U.S. Food and Drug Administration.
- CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010.
- WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017.
